Home / ARDS : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does ARDS make money? Does ARDS have pricing power? What's the Earnings Whisper? Will ARDS profit more as the business scales? What is ARDS's management track record? Is ARDS's current price justified?

Aridis Pharmaceuticals, Inc.

$0 -$0.00 (-50.00%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

Day Range

$0$0

Year Range

$0$0.05

Market Cap

4.46K

AVG Volume

14.42K

Trailing/Forward PE

-0/0

PEG ratio

-0

Dividend Yield

Next Earnings Date

2026-11-02

Primary Exchange

Other OTC

Revenue (USD) · TTM

ARDS Revenue (USD) · TTM by quarter
Period	Revenue (USD) · TTM
23 Q3	20.06M
23 Q2	19.65M
23 Q1	292K
22 Q4	292K
22 Q3	862K
22 Q2	960K
22 Q1	701K
21 Q4	701K
21 Q3	131K
21 Q2	33K

Net Income (USD) · TTM

ARDS Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
23 Q3	-1.14M
23 Q2	-10.12M
23 Q1	-30.49M
22 Q4	-31.78M
22 Q3	-35.62M
22 Q2	-47.56M
22 Q1	-44.83M
21 Q4	-43.61M
21 Q3	-39.21M
21 Q2	-23.99M

Operating Income (USD) · TTM

ARDS Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
23 Q3	-883K
23 Q2	-7.43M
23 Q1	-28.83M
22 Q4	-29.99M
22 Q3	-32.54M
22 Q2	-46.16M
22 Q1	-44.65M
21 Q4	-44.13M
21 Q3	-39.98M
21 Q2	-24.75M

EBITDA (USD) · TTM

ARDS EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
23 Q3	-574K
23 Q2	-7.05M
23 Q1	-28.39M
22 Q4	-29.51M
22 Q3	-31.02M
22 Q2	-44.66M
22 Q1	-43.2M
21 Q4	-42.71M
21 Q3	-39.62M
21 Q2	-24.39M

Cash Flows (USD) · TTM

ARDS Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
23 Q3	-17.93M
23 Q2	-21.22M
23 Q1	-23.02M
22 Q4	-29.21M
22 Q3	-24.29M
22 Q2	-28.73M
22 Q1	-29.31M
21 Q4	-23.47M
21 Q3	-25.21M
21 Q2	-22.1M

EPS (USD) · TTM

ARDS EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
23 Q3	-0.24
23 Q2	-0.75
23 Q1	-1.54
22 Q4	-1.78
22 Q3	-2.14
22 Q2	-3.32
22 Q1	-3.35
21 Q4	-3.56
21 Q3	-3.44
21 Q2	-2.4

Expenses (USD) · TTM

ARDS Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
23 Q3	23.29M
23 Q2	29.82M
23 Q1	31.88M
22 Q4	33.17M
22 Q3	34.98M
22 Q2	48.82M
22 Q1	47.17M
21 Q4	45.78M
21 Q3	41.44M
21 Q2	25.59M

Shares Outstanding · TTM

ARDS Shares Outstanding · TTM by quarter
Period	Shares Outstanding · TTM
23 Q3	-973K
23 Q2	-1.12M
23 Q1	-1.26M
22 Q4	-1.48M
22 Q3	-1.71M
22 Q2	-1.94M
22 Q1	-2.15M
21 Q4	-2.25M
21 Q3	-2.27M
21 Q2	-2.25M

Employee Count

ARDS Employee Count by quarter
Period	Employee Count
2022	37
2021	34
2020	33
2019	25
2018	23

Free Cash Flow Yield

ARDS Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-479147.92%
Sep 26	-479147.93%
Aug 26	-479147.92%
Aug 26	-479147.93%
Aug 26	-479147.93%
Aug 26	-479147.93%
Jul 26	-479147.93%
Jul 26	-479147.93%
Jul 26	-479147.92%
Jul 26	-479147.92%
Jul 26	-479147.93%
Jun 26	-119786.98%
Jun 26	-15456.38%
Jun 26	-239573.96%
Jun 26	-239573.96%
May 26	-239573.96%
May 26	-29039.27%
May 26	-239573.96%
May 26	-239573.96%
May 26	-239573.96%
Apr 26	-239573.96%
Apr 26	-239573.96%
Apr 26	-239573.96%
Apr 26	-239573.96%
Mar 26	-239573.96%
Mar 26	-239573.96%
Mar 26	-239573.96%
Mar 26	-239573.96%
Feb 26	-26619.33%
Feb 26	-239573.96%
Feb 26	-239573.96%
Feb 26	-239573.96%
Jan 26	-239573.96%
Jan 26	-239573.96%
Jan 26	-19557.06%
Jan 26	-159715.97%
Jan 26	-239573.96%
Dec 25	-239573.96%
Dec 25	-239573.96%
Dec 25	-239573.96%
Dec 25	-239573.96%
Nov 25	-239573.96%
Nov 25	-23373.07%
Nov 25	-239573.96%
Nov 25	-33044.68%
Oct 25	-239573.96%
Oct 25	-33044.68%
Oct 25	-239573.96%
Oct 25	-20832.52%
Oct 25	-239573.96%
Sep 25	-28185.17%
Sep 25	-239573.96%
Sep 25	-239573.96%
Sep 25	-95829.58%
Aug 25	-479147.93%
Aug 25	-479147.93%
Aug 25	-479147.93%
Aug 25	-479147.93%
Aug 25	-479147.93%
Jul 25	-479147.93%
Jul 25	-479147.93%
Jul 25	-479147.93%
Jul 25	-479147.93%
Jun 25	-479147.93%
Jun 25	-479147.93%
Jun 25	-479147.93%
Jun 25	-479147.93%
May 25	-479147.93%
May 25	-239573.96%
May 25	-479147.93%
May 25	-479147.93%
May 25	-479147.93%
Apr 25	-479147.93%
Apr 25	-479147.93%
Apr 25	-479147.93%
Apr 25	-479147.93%
Mar 25	-479147.93%
Mar 25	-479147.93%
Mar 25	-479147.93%
Mar 25	-479147.93%
Feb 25	-479147.93%
Feb 25	-479147.93%
Feb 25	-479147.93%
Feb 25	-479147.93%
Jan 25	-47914791.5%
Jan 25	-479147.93%
Jan 25	-479147.93%
Jan 25	-479147.93%
Jan 25	-479147.92%
Dec 24	-479147.92%
Dec 24	-479147.92%
Dec 24	-479147.92%
Dec 24	-239573.96%
Nov 24	-479147.92%
Nov 24	-479147.93%
Nov 24	-479147.93%
Nov 24	-239573.96%
Nov 24	-239573.96%
Oct 24	-479147.92%
Oct 24	-479147.93%

Price to Sales

ARDS Price to Sales by quarter
Period	Price to Sales
Sep 26	0
Sep 26	0
Aug 26	0
Aug 26	0
Aug 26	0
Aug 26	0
Jul 26	0
Jul 26	0
Jul 26	0
Jul 26	0
Jul 26	0
Jun 26	0
Jun 26	0.01
Jun 26	0
Jun 26	0
May 26	0
May 26	0
May 26	0
May 26	0
May 26	0
Apr 26	0
Apr 26	0
Apr 26	0
Apr 26	0
Mar 26	0
Mar 26	0
Mar 26	0
Mar 26	0
Feb 26	0
Feb 26	0
Feb 26	0
Feb 26	0
Jan 26	0
Jan 26	0
Jan 26	0
Jan 26	0
Jan 26	0
Dec 25	0
Dec 25	0
Dec 25	0
Dec 25	0
Nov 25	0
Nov 25	0
Nov 25	0
Nov 25	0
Oct 25	0
Oct 25	0
Oct 25	0
Oct 25	0
Oct 25	0
Sep 25	0
Sep 25	0
Sep 25	0
Sep 25	0
Aug 25	0
Aug 25	0
Aug 25	0
Aug 25	0
Aug 25	0
Jul 25	0
Jul 25	0
Jul 25	0
Jul 25	0
Jun 25	0
Jun 25	0
Jun 25	0
Jun 25	0
May 25	0
May 25	0
May 25	0
May 25	0
May 25	0
Apr 25	0
Apr 25	0
Apr 25	0
Apr 25	0
Mar 25	0
Mar 25	0
Mar 25	0
Mar 25	0
Feb 25	0
Feb 25	0
Feb 25	0
Feb 25	0
Jan 25	0
Jan 25	0
Jan 25	0
Jan 25	0
Jan 25	0
Dec 24	0
Dec 24	0
Dec 24	0
Dec 24	0
Nov 24	0
Nov 24	0
Nov 24	0
Nov 24	0
Nov 24	0
Oct 24	0
Oct 24	0

Price to Book

ARDS Price to Book by quarter
Period	Price to Book
May 20	21.99
May 20	14.78
Apr 20	15.62
Apr 20	14.76
Apr 20	15.32
Apr 20	5.65
Mar 20	5.76
Mar 20	5.52
Mar 20	5.2
Mar 20	6.31
Feb 20	6.68
Feb 20	7.32
Feb 20	5.78
Feb 20	6.26
Jan 20	6.84
Jan 20	7.54
Jan 20	7.34
Jan 20	7.02
Jan 20	4.66
Dec 19	4.16
Dec 19	4.16
Dec 19	4.57
Dec 19	5
Nov 19	5.45
Nov 19	5.06
Nov 19	4.51
Nov 19	3.85
Nov 19	4.04
Oct 19	4.16
Oct 19	4.55
Oct 19	4.25
Oct 19	5.05
Sep 19	4.9
Sep 19	5.53
Sep 19	6.4
Sep 19	8.49
Aug 19	8.72
Aug 19	6.16
Aug 19	5.78
Aug 19	3.65
Aug 19	3.66
Jul 19	4.09
Jul 19	4.25
Jul 19	4.22
Jul 19	4.46
Jun 19	4.41
Jun 19	4.91
Jun 19	3.1
Jun 19	3.97
May 19	3.77
May 19	4.04
May 19	4.07
May 19	2.84
May 19	2.98
Apr 19	3.08
Apr 19	2.97
Apr 19	3.12
Apr 19	3.48
Mar 19	3.51
Mar 19	1.49
Mar 19	1.2
Mar 19	1.14
Mar 19	1.11
Feb 19	1.11
Feb 19	1.08
Feb 19	1.1
Feb 19	1.04
Jan 19	1.11
Jan 19	1.15
Jan 19	1.23
Jan 19	1.28
Dec 18	1.32
Dec 18	1.02
Dec 18	1.23
Dec 18	1.09
Nov 18	1.36
Nov 18	1.53
Nov 18	1.62
Nov 18	43.66
Nov 18	44.22
Oct 18	44.66
Oct 18	45.2
Oct 18	45.91
Oct 18	46.52
Sep 18	47.21
Sep 18	25.02
Sep 18	24.82
Sep 18	25.25
Aug 18	28.02
Aug 18	27.16
Aug 18	26.93

No video analysis for this stock yet. Request one from our team.

News: ARDS

gurufocus.com · 13 Sep 2026

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positi

AI Analysis

Aridis Pharmaceuticals, Inc.

Video analysis: ARDS

News: ARDS

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

Similar companies